- $3.78bn
- $3.37bn
- $401.20m
- 89
- 23
- 81
- 70
Annual balance sheet for Cellebrite DI, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 238 | 182 | 184 | 303 | 447 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 69.5 | 73.1 | 85.8 | 83.4 | 89.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 324 | 273 | 296 | 422 | 568 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 16.1 | 16.8 | 32.9 | 30.2 | 27.6 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 364 | 340 | 403 | 533 | 691 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 159 | 187 | 208 | 254 | 296 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 199 | 413 | 329 | 499 | 355 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 165 | -73.3 | 73.9 | 34.2 | 336 |
| Total Liabilities & Shareholders' Equity | 364 | 340 | 403 | 533 | 691 |
| Total Common Shares Outstanding |